Related Experiment Video
Updated: Oct 2, 2025
03:55
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
644
Poorly differentiated thyroid carcinoma: a clinician's perspective
Junyu Tong1,2, Maomei Ruan2,3, Yuchen Jin2
1Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.
European Thyroid Journal
|February 23, 2022
Summary
Poorly differentiated thyroid carcinoma (PDTC) is rare, with diagnosis and treatment challenging due to limited data. Early surgical resection improves prognosis, while advanced cases require multimodal adjuvant therapies and further research into novel treatments.
Area of Science:
- Endocrinology
- Oncology
- Pathology
Background:
- Poorly differentiated thyroid carcinoma (PDTC) is a rare malignancy arising from follicular cells.
- Limited clinical data complicates consensus on diagnosis and treatment, impacting patient outcomes.
- A comprehensive review is needed to consolidate current knowledge and guide clinical practice.
Purpose of the Study:
- To provide a clinician's perspective on the epidemiology, diagnosis, prognosis, and therapeutics of PDTC.
- To summarize current diagnostic criteria, including the Turin consensus.
- To review traditional and emerging treatment strategies for PDTC.
Main Methods:
- Comprehensive literature review focusing on clinical data, pathology, and medical imaging.
- Analysis of diagnostic criteria, particularly the Turin consensus.
- Evaluation of traditional (surgery, 131I therapy, radiation, chemotherapy) and emerging (targeted therapy, differentiation therapy, immunotherapy) treatment modalities.
Main Results:
- The Turin consensus serves as the primary diagnostic standard for PDTC.
- Individualized treatment approaches are crucial for optimal patient management.
- Complete resection at an early stage offers the best prognosis; advanced or metastatic disease requires adjuvant therapies.
Conclusions:
- PDTC management necessitates tailored treatment strategies based on individual patient assessments.
- Adjuvant therapies are essential for patients with locally advanced or metastatic PDTC.
- Further investigation into emerging therapies is critical to enhance outcomes for advanced PDTC cases.
